Bio-Techne Corporation (TECH)
Summary
TECH Chart
CMB.TECH: Q2 Was Strong, But Valuation Looks Full (Downgrade)
CMB.TECH (CMBT) shows improved earnings quality as core shipping EBITDA rises despite reduced ship sales. Q2 revenue and EBITDA surged, but backlog growth stalled, raising concerns about long-term contract momentum. A strategic ammonia-powered vessel agreement with Fortescue signals tangible progress in clean fuel initiatives.
CMB.TECH Q2 Earnings Call Highlights
CMB.TECH NYSE: CMBT reported second-quarter 2026 net profit of $364.4 million, supported by revenue of more than $700 million and $127 million in gains from vessel sales, as shipping markets remained strong across several of the company's operating segments.
TECH Q4 Earnings Meet Estimates, Revenues Surpass, Stock Rises
Bio-Techne's Q4 revenues beat estimates as Diagnostics and Spatial Biology deliver strong organic growth, while its Merck deal remains in focus.
Bio-Techne Corporation Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 18,736 | $986,485.55 | $1.35M | $364,192.62 | 36.92% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 9,682 | $684,020 | $699,911.78 | $15,891.78 | 2.32% |
| PER Paul E. Rasmussen SIT INVESTMENT ASSOCIATES Inc. | 31,875 | $2.89M | $2.3M | -$591,982.65 | -20.45% |
| ABB Alexander Bjornager Bonde Danske Bank A/S | 100 | $5,881 | $7,212 | $1,331 | 22.63% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 1,730 | $91,695.71 | $124,957.9 | $33,262.19 | 36.27% |
Bio-Techne Corporation Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Dan Leonard RBC Capital | 75.1 | $5,102.97 | $5,431.33 | $328.36 | 6.43% |
Bio-Techne Corporation (TECH) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Bio-Techne Corporation ever had a stock split?
Bio-Techne Corporation Profile
| Biotechnology Industry | Healthcare Sector | Kim Kelderman CEO | NASDAQ (NGS) Exchange | 09073M104 CUSIP |
| US Country | 3,000 Employees | 17 Aug 2026 Last Dividend | 30 Nov 2022 Last Split | 9 Feb 1989 IPO Date |
Overview
Bio-Techne Corporation operates at the forefront of the life science sector, providing a comprehensive range of products and services crucial for research, clinical diagnostics, and therapeutic development. With a global footprint, the company serves a diverse clientele spread across the United States, the United Kingdom, rest of Europe, Middle East, Africa, Greater China, and the rest of the Asia-Pacific region. Bio-Techne is structured into two main operational segments: Protein Sciences, and Diagnostics and Genomics, each addressing different needs within the life sciences and diagnostics sectors. Originally established in 1976 under the name Techne Corporation, the organization underwent a rebranding to Bio-Techne Corporation in November 2014 and is based in Minneapolis, Minnesota. This strategic evolution reflects its broadened focus beyond its initial scope, signaling its expansion into a comprehensive suite of technologies and services catering to the dynamic requirements of biological research and clinical diagnostics.
Products and Services
Bio-Techne Corporation distinguishes itself through its broad portfolio of products and services across two main segments:
- Protein Sciences: The cornerstone of Bio-Techne's offerings, this segment focuses on the development and manufacturing of biological reagents critical for life science research, diagnostics, and cell and gene therapy advancements. Products include:
- Cytokines and growth factors: Essential for studying cell signaling and communication.
- Antibodies: Integral for detecting and quantifying target proteins.
- Small molecules: Used in various experimental applications to modulate biological processes.
- Tissue culture sera: Provides a nutritious environment for cell culture growth.
- Cell selection technologies: Enables the isolation of specific cell types for research or therapeutic use.
- Proteomic analytical tools: Includes instruments and immunoassays for protein analysis in biological fluids, facilitating automated western blot and multiplexed ELISA workflows.
- Diagnostics and Genomics: This segment is geared towards the development and manufacture of products for the regulated diagnostics market as well as for research and clinical applications involving genomics and oncology. Offerings include:
- Diagnostic products: Comprising controls, calibrators, and assays for quality assurance in diagnostic testing.
- Exosome-based molecular diagnostic assays: Innovative solutions for detecting disease markers at a molecular level.
- Tissue-based in-situ hybridization assays: Advanced tools for spatial genomic analysis and biopsy examination.
- Genetic and oncology kits: Facilitate research and clinical applications in genetics and cancer diagnostics.
- Carrier screening and oncology diagnostics: Support genetic testing and cancer detection and monitoring.
- Molecular controls: Provide benchmarks for ensuring accuracy in molecular diagnostic tests.
- Process control products: Essential for maintaining quality in hematology, blood chemistry, and coagulation diagnostics.
